A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31
- Registration Number
- NCT00133185
- Locations
- 🇨🇳
Machay Memorial Hospital, Taipei, Taiwan
Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
- Conditions
- Coronary Arteriosclerosis
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11
- Registration Number
- NCT00129038
- Locations
- 🇮🇪
9.169.02 St. James' Hospital, Dublin 8, Ireland
🇮🇪9.169.01 Dept of Clinical Pharmacology, Dublin 9, Ireland
High Dose Trial in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 78
- Registration Number
- NCT00128440
- Locations
- 🇺🇸
Boehringer Ingelheim Investigational Site, Tacoma, Washington, United States
Dose Finding Study in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 389
- Registration Number
- NCT00122434
- Locations
- 🇺🇸
McGuire VA, Fredericksburg, Virginia, United States
🇳🇱Academisch Ziekenhuis Nijmegen St. Radbout, Nijmegen, Netherlands
🇳🇱Gelre Ziekenhuizen, Zutphen, Netherlands
Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-04-01
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 166
- Registration Number
- NCT00106821
- Locations
- 🇺🇸
LSU MC-Sheveport, Shreveport, Louisiana, United States
🇺🇸VAMC Houston, Houston, Texas, United States
🇺🇸Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
- Conditions
- HIV Infections
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00097799
- Locations
- 🇺🇸
1182.70.066, Los Angeles, California, United States
🇺🇸1182.70.174, Macon, Georgia, United States
🇺🇸1182.70.071, Los Angeles, California, United States
Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma
- Conditions
- Asthma
- First Posted Date
- 2004-11-15
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 113
- Registration Number
- NCT00096616
- Locations
- 🇺🇸
Ben Taul General Hospital, Houston, Texas, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
🇺🇸620 South 20th Street, NHB 104, Birmingham, Alabama, United States
Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2010-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 600
- Registration Number
- NCT00003328
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, United States
🇺🇸Health Advance Institute, Peoria, Illinois, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children
- First Posted Date
- 2004-02-10
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 115
- Registration Number
- NCT00076999
- Locations
- 🇨🇦
1182.14.11002 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇺🇸1182.14.00003 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸1182.14.00010 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States
Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00062660
- Locations
- 🇺🇸
1182.58.20 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸1182.58.18 University of Texas Southwest Medical Center at Dallas, Dallas, Texas, United States
🇦🇺1182.58.61012 Bigge Park Centre, Liverpool, New South Wales, Australia